OptionsHouse

Options Trading News

October 12, 2012  Fri 7:31 AM CT

LXRX: SEE CHART GET CHAIN FIND STRATEGIES

Drug Progresses to Final Stage of Testing

Lexicon Pharmaceuticals reported positive data for its drug that treats carcinoid tumors. It's now moving from Phase 2 trials to Phase 3 trials, sending LXRX higher by 13 percent in the premarket.

Infosys Sees Weaker Profit

Infosys now expect full-year earnings of $2.97 a share, versus its previous forecast of $3.03.The outsourcing company also failed to raise it revenue guidance as analysts had hoped. INFY drops 5 percent in early trading.

J.B. Hunt Revenue Beats Expectations

J.B. Hunt Transport Services had third-quarter revenue of $1.30 billion, beating the $1.28 billion estimate. Profit missed expectations, but investors are focusing on that strong top-line number and sending JBHT higher by about 5 percent in the premarket.

Weak PC Market Drags on AMD

Advanced Micro Devices preannounced that third-quarter revenue fell by about 10 percent. It had previously forecast a decline of no more than 4 percent. Management cited a weakening PC market, and AMD is lower by 9 percent in the pre.

Share this article with your friends


OptionsHouse

Premium Services

Upcoming Webinar:

Using Options For Income

http://bit.ly/1nY1OKA

Jon Najarian and Adam Mesh of Options Wealth Machine discuss a detailed strategy utilizing credit spreads to generate income, and how any level of trader can use this simple trading technique.

Education & Strategy

Sweet Spot Exceptions

As discussed last week, when using the Stock Replacement Strategy to replace a stock position to trade direction, we want to use an option that has very similar characteristics to the stock. We talked about using the deep in-the-money, 80 to 85 delta option that is similar in the Greeks and has relatively little extrinsic value which tends to work against us in stock directional trading.

View more education articles »